疫苗生产商诺瓦瓦克斯医药的第二大股东Shah Capital敦促这家生物技术公司的董事会进行战略调整，包括潜在的出售，并警告称如果在未来四个月内没有任何进展，可能会发起代理权争夺战。Shah Capital表示，对该公司疲软的新冠疫苗销售越来越不满。据悉，Shah Capital的持股比例从10月的7.2%增至约8.3%。
疫苗生产商诺瓦瓦克斯医药的第二大股东Shah Capital敦促这家生物技术公司的董事会进行战略调整，包括潜在的出售，并警告称如果在未来四个月内没有任何进展，可能会发起代理权争夺战。Shah Capital表示，对该公司疲软的新冠疫苗销售越来越不满。据悉，Shah Capital的持股比例从10月的7.2%增至约8.3%。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.